According to a new report from Intel Market Research, the global Nivolumab market was valued at USD 7.85 billion in 2025 and is projected to reach USD 14.76 billion by 2034, growing at a CAGR of 7.3% during the forecast period (2026-2034). This growth is driven by the increasing prevalence of cancer worldwide, expanding applications of immunotherapy, and growing adoption of PD-1 inhibitors in...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek